Pyxis Oncology Inc [PYXS] stock is trading at $3.75, up 16.10%. An important factor to consider is whether the stock is rising or falling in short-term value. The PYXS shares have gain 16.10% over the last week, with a monthly amount glided 1.90%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Pyxis Oncology Inc [NASDAQ: PYXS] stock has seen the most recent analyst activity on August 08, 2024, when Stifel initiated its Buy rating and assigned the stock a price target of $10. On February 09, 2024, BTIG Research initiated with a Buy rating and assigned a price target of $8 on the stock. Leerink Partners started tracking the stock assigning a Outperform rating and suggested a price target of $12 on January 23, 2024. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $7 as its price target on September 05, 2023. Jefferies started tracking with a Buy rating for this stock on November 02, 2021, and assigned it a price target of $25. In a note dated November 02, 2021, Credit Suisse initiated an Outperform rating and provided a target price of $19 on this stock.
Pyxis Oncology Inc [PYXS] stock has fluctuated between $1.35 and $6.85 over the past year. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Pyxis Oncology Inc [NASDAQ: PYXS] shares were valued at $3.75 at the most recent close of the market. An investor can expect a potential return of 140.0% based on the average PYXS price forecast.
Analyzing the PYXS fundamentals
Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -3.51%, Pretax Profit Margin comes in at -3.03%, and Net Profit Margin reading is -3.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.38 and Total Capital is -0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.39 points at the first support level, and at 3.03 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.95, and for the 2nd resistance point, it is at 4.15.
Ratios To Look Out For
For context, Pyxis Oncology Inc’s Current Ratio is 9.53. On the other hand, the Quick Ratio is 9.53, and the Cash Ratio is 1.57. Considering the valuation of this stock, the price to sales ratio is 13.80, the price to book ratio is 1.30.
